Pyridoxine Add-On Treatment for the Control of Behavioral Adverse Effects Induced by Levetiracetam in Children: A Case-Control Prospective Study
- PMID: 29442544
- DOI: 10.1177/1060028018759637
Pyridoxine Add-On Treatment for the Control of Behavioral Adverse Effects Induced by Levetiracetam in Children: A Case-Control Prospective Study
Abstract
Background: Few studies on adult and pediatric patients have shown pyridoxine efficacy as additional therapy for those receiving levetiracetam (LEV) to prevent and mitigate behavioral adverse effects (BAEs).
Objective: The aim of our study was to analyze the safety and efficacy of pyridoxine supplementation in the prevention of LEV adverse effects, including suicidal ideation.
Methods: This randomized, case-control trial included patients receiving LEV as monotherapy treatment. Patients were subdivided into 2 groups, according to whether they were treated with LEV only (group 1) or LEV with supplemental pyridoxine (group 2).
Results: In both cohorts, the most frequent BAEs were irritability/aggression followed by depression and confusion. Those patients (92%) who initiated pyridoxine after 1 month of LEV treatment did not need to change or suspend LEV ( P < 0.001), and BAE improved after 9.06 ± 3.05 days of pyridoxine supplementation. None of the patients complained of symptoms of pyridoxine toxicity, and no new adverse effects of LEV off-label were reported.
Conclusions: In our study, we found pyridoxine to be safe and effective in controlling LEV-induced BAEs in children.
Keywords: behavioral adverse effects; child; levetiracetam; pyridoxine.
Similar articles
-
Current evidence for adjunct pyridoxine (vitamin B6) for the treatment of behavioral adverse effects associated with levetiracetam: A systematic review.Epilepsy Behav. 2023 Mar;140:109065. doi: 10.1016/j.yebeh.2022.109065. Epub 2023 Feb 13. Epilepsy Behav. 2023. PMID: 36791631 Review.
-
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.Epilepsy Behav. 2021 May;118:107939. doi: 10.1016/j.yebeh.2021.107939. Epub 2021 Apr 8. Epilepsy Behav. 2021. PMID: 33839453 Review.
-
Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.Epilepsy Behav. 2020 Feb;103(Pt A):106861. doi: 10.1016/j.yebeh.2019.106861. Epub 2020 Jan 6. Epilepsy Behav. 2020. PMID: 31917143
-
Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.Eur J Paediatr Neurol. 2019 Jan;23(1):197-203. doi: 10.1016/j.ejpn.2018.10.004. Epub 2018 Nov 2. Eur J Paediatr Neurol. 2019. PMID: 30424990 Clinical Trial.
-
Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results.Epilepsy Behav. 2008 Oct;13(3):557-9. doi: 10.1016/j.yebeh.2008.07.004. Epub 2008 Aug 3. Epilepsy Behav. 2008. PMID: 18647662 Clinical Trial.
Cited by
-
Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios.Front Pharmacol. 2022 Oct 6;13:991244. doi: 10.3389/fphar.2022.991244. eCollection 2022. Front Pharmacol. 2022. PMID: 36278161 Free PMC article. Review.
-
Dietary Vitamin B Complex: Orchestration in Human Nutrition throughout Life with Sex Differences.Nutrients. 2022 Sep 22;14(19):3940. doi: 10.3390/nu14193940. Nutrients. 2022. PMID: 36235591 Free PMC article. Review.
-
Depression and Anxiety in the Epilepsies: from Bench to Bedside.Curr Neurol Neurosci Rep. 2020 Jul 14;20(9):41. doi: 10.1007/s11910-020-01065-z. Curr Neurol Neurosci Rep. 2020. PMID: 32666148 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
